Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
Intellia Therapeutics (NTLA) Receives a Buy From J.P. Morgan
Buy Rating Affirmed for Intellia Therapeutics Following Successful Phase II Trials and Strong Cash Reserves
Intellia Therapeutics Analyst Ratings
Evercore ISI Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
RBC Cuts Price Target on Intellia Therapeutics to $54 From $60, Keeps Outperform, Speculative Risk
Barclays Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Intellia Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)
Oppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings